All Trials

A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors and ECOG 0–2, including a cohort with moderate hepatic impairment (bilirubin >1.5×–≤3× ULN), receive sacituzumab govitecan-hziy (Trop-2–targeted ADC delivering SN-38) on Days 1 and 8; dose-escalation (5→7.5→10 mg/kg) is tested in the impaired-liver cohort with a normal-liver comparator at 10 mg/kg. Excludes recent irinotecan, active CNS disease, Gilbert’s syndrome, strong UGT1A1 modulators, and significant liver-related complications in the impaired cohort.

ClinicalTrials.gov ID: NCT04617522

A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable hepatocellular carcinoma or liver-only metastases receive Y-90 radioembolization (TheraSphere) followed by PET-CT–guided SBRT boost to underdosed tumor regions, with strict liver function and no progressive extrahepatic disease required. Aims to assess hepatic decompensation risk and early local control using adaptive dosimetry.

ClinicalTrials.gov ID: NCT04518748

First in Human Dose Escalation Study of AU409 in Patients With Advanced Primary Liver Cancers or Advanced Solid Tumor With Liver Predominant Metastatic Disease

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced primary liver cancers (HCC or cholangiocarcinoma) or solid tumors with liver‑predominant metastases (≤2 extrahepatic sites), ECOG 0–1, receive oral AU409 in 28‑day cycles. AU409 is a first‑in‑class small‑molecule RNA transcription modulator designed to alter liver cancer transcription programs; key exclusions include untreated/symptomatic CNS metastases, significant cardiac risk, Child‑Pugh ≥B7 (for HCC), and strong CYP inducer/inhibitor use.

ClinicalTrials.gov ID: NCT05791448

Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced, GPC3-positive hepatocellular carcinoma (≥25% by IHC) who have progressed on or are intolerant to first-line therapy receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of autologous GPC3-targeted CAR-T cells (humanized anti-GPC3 hYP7) that recognize glypican-3 to mediate tumor cell killing. Key exclusions include Child-Pugh B/C and uncontrolled comorbidities; controlled HBV/HCV and stable treated brain metastases are allowed.

ClinicalTrials.gov ID: NCT05003895

A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.

ClinicalTrials.gov ID: NCT07001592

A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/ablation-ineligible advanced hepatocellular carcinoma requiring systemic therapy receive concurrent stereotactic body radiotherapy (escalating doses) plus atezolizumab (anti–PD-L1) and bevacizumab (anti-VEGF). Designed to assess safety and preliminary efficacy of the triplet and define the SBRT dose to combine with this standard immunotherapy/anti-angiogenic regimen.

ClinicalTrials.gov ID: NCT05488522

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) receive IV TORL-4-500 monotherapy every 3 weeks; TORL-4-500 is a DLK1-targeted antibody–drug conjugate (humanized anti-DLK1 IgG1 linked to MMAE via a val-cit linker) intended for DLK1-expressing tumors. Key exclusions include uncontrolled/symptomatic brain mets, significant cardiac disease, active infections, unresolved prior toxicities, and recent other malignancies.

ClinicalTrials.gov ID: NCT06005740

A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic HCC (Child-Pugh A–B7) after ≥1 prior systemic therapy and harboring a WNT-pathway–activating alteration receive ALN-BCAT, an IV siRNA that silences CTNNB1 (β-catenin) via hepatic LNP delivery, as monotherapy or combined with pembrolizumab. Excludes fibrolamellar/sarcomatoid/mixed cholangio-HCC and symptomatic extrahepatic disease; aims to define dose and assess preliminary activity, with the combo exploring β-catenin suppression to enhance PD-1 response.

ClinicalTrials.gov ID: NCT06600321

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic HCC (Child-Pugh A; BCLC B not LRT-eligible or C) or other advanced solid tumors harboring activating FGFR3/FGFR4 alterations or focal FGF19 amplification; prior FGFR inhibitors allowed in dose-escalation but excluded for FGFR4/pan-FGFR in HCC expansion. Patients receive oral TYRA-430, a reversible, FGFR4/FGFR3-biased tyrosine kinase inhibitor targeting FGF19/FGFR-driven tumors.

ClinicalTrials.gov ID: NCT06915753

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with centrally confirmed GPC3-positive advanced or metastatic solid tumors—emphasizing HCC (BCLC B not eligible for LRT or C, Child-Pugh A, ECOG 0–1)—receive AZD9793 monotherapy given IV or SC after prior therapy (Part A: ≥1 prior line; Part B: ≤1 prior line). AZD9793 is an asymmetric trispecific T-cell engager targeting GPC3 and engaging the TCR and CD8 co-receptor to bias CD8+ activation; exclusions include prior GPC3-targeted therapy and significant autoimmune, cardiac/CNS disease, or active infections.

ClinicalTrials.gov ID: NCT06795022